Titre : Produits du tabac

Produits du tabac : Questions médicales fréquentes

Termes MeSH sélectionnés :

Partial Thromboplastin Time

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment diagnostiquer une dépendance au tabac ?

Le diagnostic repose sur des questionnaires d'auto-évaluation et l'observation des symptômes de sevrage.
Dépendance au tabac Diagnostic médical
#2

Quels tests pour évaluer les effets du tabac ?

Des tests de fonction pulmonaire et des analyses de sang peuvent évaluer les effets du tabac.
Tests de fonction pulmonaire Tabagisme

Symptômes 2

#1

Quels sont les symptômes d'une intoxication au tabac ?

Les symptômes incluent nausées, vertiges, maux de tête et palpitations cardiaques.
Intoxication au tabac Symptômes
#2

Comment le tabac affecte-t-il la respiration ?

Le tabac provoque une toux chronique, un essoufflement et une diminution de la capacité pulmonaire.
Tabagisme Maladies respiratoires

Prévention 2

#1

Comment prévenir le tabagisme chez les jeunes ?

L'éducation, les campagnes de sensibilisation et les politiques anti-tabac sont essentielles.
Prévention du tabagisme Éducation à la santé
#2

Les lois anti-tabac sont-elles efficaces ?

Oui, elles réduisent la consommation de tabac et protègent les non-fumeurs de l'exposition.
Législation anti-tabac Santé publique

Traitements 2

#1

Quels traitements existent pour arrêter de fumer ?

Les traitements incluent les substituts nicotiniques, les médicaments et la thérapie comportementale.
Sevrage tabagique Traitement médicamenteux
#2

Les thérapies comportementales sont-elles efficaces ?

Oui, elles augmentent les chances d'arrêter de fumer en modifiant les comportements liés au tabagisme.
Thérapie comportementale Dépendance au tabac

Complications 2

#1

Quelles sont les complications du tabagisme ?

Les complications incluent le cancer, les maladies cardiovasculaires et les maladies respiratoires chroniques.
Complications du tabagisme Maladies cardiovasculaires
#2

Le tabac augmente-t-il le risque de cancer ?

Oui, le tabac est un facteur de risque majeur pour plusieurs types de cancer, notamment le poumon.
Cancer du poumon Tabagisme

Facteurs de risque 2

#1

Quels sont les facteurs de risque du tabagisme ?

Les facteurs incluent l'âge, l'environnement social, et l'exposition à des antécédents familiaux.
Facteurs de risque Tabagisme
#2

Le stress influence-t-il la consommation de tabac ?

Oui, le stress peut augmenter la consommation de tabac chez les individus dépendants.
Stress Dépendance au tabac
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Produits du tabac : Questions médicales les plus fréquentes", "headline": "Produits du tabac : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Produits du tabac : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-18", "dateModified": "2025-02-12", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Produits du tabac" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Dispositifs pour fumer", "url": "https://questionsmedicales.fr/mesh/D000074602", "about": { "@type": "MedicalCondition", "name": "Dispositifs pour fumer", "code": { "@type": "MedicalCode", "code": "D000074602", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.637.767" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Tabac sans fumée", "alternateName": "Tobacco, Smokeless", "url": "https://questionsmedicales.fr/mesh/D014030", "about": { "@type": "MedicalCondition", "name": "Tabac sans fumée", "code": { "@type": "MedicalCode", "code": "D014030", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.637.767.844.500" } } }, { "@type": "MedicalWebPage", "name": "Tabac pour pipe à eau", "alternateName": "Tobacco, Waterpipe", "url": "https://questionsmedicales.fr/mesh/D000073846", "about": { "@type": "MedicalCondition", "name": "Tabac pour pipe à eau", "code": { "@type": "MedicalCode", "code": "D000073846", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.637.767.844.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Produits du tabac", "alternateName": "Tobacco Products", "code": { "@type": "MedicalCode", "code": "D062789", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Takahiro Tabuchi", "url": "https://questionsmedicales.fr/author/Takahiro%20Tabuchi", "affiliation": { "@type": "Organization", "name": "Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, Japan." } }, { "@type": "Person", "name": "Jennifer B Unger", "url": "https://questionsmedicales.fr/author/Jennifer%20B%20Unger", "affiliation": { "@type": "Organization", "name": "Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America." } }, { "@type": "Person", "name": "Pamela M Ling", "url": "https://questionsmedicales.fr/author/Pamela%20M%20Ling", "affiliation": { "@type": "Organization", "name": "Center for Tobacco Control Research and Education, University of California, San Francisco, San Francisco, California." } }, { "@type": "Person", "name": "Silvano Gallus", "url": "https://questionsmedicales.fr/author/Silvano%20Gallus", "affiliation": { "@type": "Organization", "name": "Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy." } }, { "@type": "Person", "name": "Jessica L Barrington-Trimis", "url": "https://questionsmedicales.fr/author/Jessica%20L%20Barrington-Trimis", "affiliation": { "@type": "Organization", "name": "Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America. Electronic address: jtrimis@usc.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!", "datePublished": "2023-06-17", "url": "https://questionsmedicales.fr/article/37374373", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/medicina59061169" } }, { "@type": "ScholarlyArticle", "name": "Comparative analysis on characteristics of two activated partial thromboplastin time reagents.", "datePublished": "2022-07-19", "url": "https://questionsmedicales.fr/article/35853032", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jcla.24608" } }, { "@type": "ScholarlyArticle", "name": "Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies: Current State of the Art.", "datePublished": "2022-09-02", "url": "https://questionsmedicales.fr/article/36055261", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/s-0042-1756196" } }, { "@type": "ScholarlyArticle", "name": "Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population.", "datePublished": "2022-10-15", "url": "https://questionsmedicales.fr/article/36292752", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/genes13101867" } }, { "@type": "ScholarlyArticle", "name": "Activated Partial Thromboplastin Time and Mortality in Coronary Artery Bypass Grafting Patients.", "datePublished": "2022-09-17", "url": "https://questionsmedicales.fr/article/36168325", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/2918654" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Technologie, industrie et agriculture", "item": "https://questionsmedicales.fr/mesh/D013676" }, { "@type": "ListItem", "position": 3, "name": "Produits manufacturés", "item": "https://questionsmedicales.fr/mesh/D008420" }, { "@type": "ListItem", "position": 4, "name": "Dispositifs pour fumer", "item": "https://questionsmedicales.fr/mesh/D000074602" }, { "@type": "ListItem", "position": 5, "name": "Produits du tabac", "item": "https://questionsmedicales.fr/mesh/D062789" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Produits du tabac - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Produits du tabac", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-30", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Produits du tabac", "description": "Comment diagnostiquer une dépendance au tabac ?\nQuels tests pour évaluer les effets du tabac ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Partial+Thromboplastin+Time#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Produits du tabac", "description": "Quels sont les symptômes d'une intoxication au tabac ?\nComment le tabac affecte-t-il la respiration ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Partial+Thromboplastin+Time#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Produits du tabac", "description": "Comment prévenir le tabagisme chez les jeunes ?\nLes lois anti-tabac sont-elles efficaces ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Partial+Thromboplastin+Time#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Produits du tabac", "description": "Quels traitements existent pour arrêter de fumer ?\nLes thérapies comportementales sont-elles efficaces ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Partial+Thromboplastin+Time#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Produits du tabac", "description": "Quelles sont les complications du tabagisme ?\nLe tabac augmente-t-il le risque de cancer ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Partial+Thromboplastin+Time#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Produits du tabac", "description": "Quels sont les facteurs de risque du tabagisme ?\nLe stress influence-t-il la consommation de tabac ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Partial+Thromboplastin+Time#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dépendance au tabac ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des questionnaires d'auto-évaluation et l'observation des symptômes de sevrage." } }, { "@type": "Question", "name": "Quels tests pour évaluer les effets du tabac ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de fonction pulmonaire et des analyses de sang peuvent évaluer les effets du tabac." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une intoxication au tabac ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent nausées, vertiges, maux de tête et palpitations cardiaques." } }, { "@type": "Question", "name": "Comment le tabac affecte-t-il la respiration ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Le tabac provoque une toux chronique, un essoufflement et une diminution de la capacité pulmonaire." } }, { "@type": "Question", "name": "Comment prévenir le tabagisme chez les jeunes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation, les campagnes de sensibilisation et les politiques anti-tabac sont essentielles." } }, { "@type": "Question", "name": "Les lois anti-tabac sont-elles efficaces ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles réduisent la consommation de tabac et protègent les non-fumeurs de l'exposition." } }, { "@type": "Question", "name": "Quels traitements existent pour arrêter de fumer ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent les substituts nicotiniques, les médicaments et la thérapie comportementale." } }, { "@type": "Question", "name": "Les thérapies comportementales sont-elles efficaces ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles augmentent les chances d'arrêter de fumer en modifiant les comportements liés au tabagisme." } }, { "@type": "Question", "name": "Quelles sont les complications du tabagisme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent le cancer, les maladies cardiovasculaires et les maladies respiratoires chroniques." } }, { "@type": "Question", "name": "Le tabac augmente-t-il le risque de cancer ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabac est un facteur de risque majeur pour plusieurs types de cancer, notamment le poumon." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque du tabagisme ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, l'environnement social, et l'exposition à des antécédents familiaux." } }, { "@type": "Question", "name": "Le stress influence-t-il la consommation de tabac ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut augmenter la consommation de tabac chez les individus dépendants." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 12/02/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Jennifer B Unger

4 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Pamela M Ling

4 publications dans cette catégorie

Affiliations :
  • Center for Tobacco Control Research and Education, University of California, San Francisco, San Francisco, California.
Publications dans "Produits du tabac" :

Silvano Gallus

3 publications dans cette catégorie

Affiliations :
  • Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
Publications dans "Produits du tabac" :

Jessica L Barrington-Trimis

3 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America. Electronic address: jtrimis@usc.edu.

Mary Ann Pentz

3 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Rob McConnell

3 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Lisa Henriksen

3 publications dans cette catégorie

Affiliations :
  • Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California, USA.
Publications dans "Produits du tabac" :

William G Shadel

3 publications dans cette catégorie

Affiliations :
  • RAND Corporation, Pittsburgh, PA, USA.

Joan S Tucker

3 publications dans cette catégorie

Affiliations :
  • RAND Corporation, Santa Monica, CA, USA.

Reinskje Talhout

3 publications dans cette catégorie

Affiliations :
  • National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

Elisa Borroni

2 publications dans cette catégorie

Affiliations :
  • Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
Publications dans "Produits du tabac" :

Anna Odone

2 publications dans cette catégorie

Affiliations :
  • Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy.
  • School of Medicine, University Vita-Salute San Raffaele, 20132 Milan, Italy.
Publications dans "Produits du tabac" :

Piet A van den Brandt

2 publications dans cette catégorie

Affiliations :
  • Department of Epidemiology, CAPHRI-School for Public Health and Primary Care, Maastricht University Medical Centre, 6211 LK Maastricht, The Netherlands.
  • Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, 6211 LK Maastricht, The Netherlands.
Publications dans "Produits du tabac" :

Giuseppe Gorini

2 publications dans cette catégorie

Affiliations :
  • Oncologic Network, Prevention and Research Institute (ISPRO), 50139 Florence, Italy.
Publications dans "Produits du tabac" :

Alessandra Lugo

2 publications dans cette catégorie

Affiliations :
  • Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
Publications dans "Produits du tabac" :

Satomi Odani

2 publications dans cette catégorie

Affiliations :
  • Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, Japan.

Irfan Rahman

2 publications dans cette catégorie

Affiliations :
  • Department of Environmental Medicine, University of Rochester Medical Center, Rochester, United States.

Tess Boley Cruz

2 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Robert Urman

2 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Sources (10000 au total)

Comparative analysis on characteristics of two activated partial thromboplastin time reagents.

For the lack of standardized activated partial thromboplastin time (APTT), it has been pointed out that there are differences in values among several reagents. Recently, we have performed a parallel m... In order to clarify the factors related to ΔAPTT, multiple regression analysis was performed on 8324 samples, using clinical laboratory data of all test items requested simultaneously with APTT. To co... Multiple regression analysis detected albumin-globulin ratio (AGR), C-reactive protein (CRP), hematocrit, and prothrombin time as factors related to ΔAPTT (p < 0.001). Results revealed no significant ... It is considered that the pseudo-prolongation of APTT is triggered by the interaction of CRP on the phospholipid in Coagpia APTT-n, which contributed to the APTT dissociation....

Activated Partial Thromboplastin Time and Mortality in Coronary Artery Bypass Grafting Patients.

To evaluate the prognostic value of preoperative activated partial thromboplastin time (APTT) in patients who underwent coronary artery bypass grafting (CABG).... All data were extracted from the Medical Information Mart for Intensive Care III (MIMIC-III) database. The study population was divided to two groups according to the optimal cut-off value of APTT cal... A total of 2,706 patients were included. The optimal cut-off value of APTT for 4-year mortality was 44 seconds. The Cox proportional hazard model showed that patients with APTT ≥ 44 had a significantl... A longer APTT (≥44) was associated with a higher risk of mortality and can serve as a prognostic predictor in CABG patients....

Activated partial thromboplastin time as a potential biomarker for the diagnosis of tuberculous pleural effusion.

The aim of this study was to explore the difference in activated partial thromboplastin time (APTT) levels in patients with tuberculous and non-tuberculous pleural effusion (TPE and non-TPE) and its p... A total of 61 patients diagnosed with tuberculous pleurisy with pleural effusion at Shunde Hospital of Southern Medical University from July 2013 to September 2020 were selected as the observation gro... The levels of APTT and ADA in the TPE group were significantly higher than the control group, and were 40.03 (37.00, 42.60) (s) and 55.00 (47.00, 69.25) (U/L) for TPE, 29.50 (25.45, 34.20) (s) and 11.... The level of plasma APTT has certain significance in differentiating tuberculous pleural effusion from nontuberculous pleural effusion....

Association of prothrombin time, thrombin time and activated partial thromboplastin time levels with preeclampsia: a systematic review and meta-analysis.

Preeclampsia (PE), an obstetric disorder, remains one of the leading causes of maternal and infant mortality worldwide. In individuals with PE, the coagulation-fibrinolytic system is believed to be am... This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. Articles relevant to the study, published from July 26, 2013, to July 26, 2023, were systematically sea... A total of 30 articles, involving 5,964 individuals (2,883 with PE and 3,081 as normotensive pregnant mothers), were included in this study. The overall pooled SMD for PT, APTT, and TT between PE and ... The meta-analysis underscores the association between PE and prolonged PT and APTT. This suggests that evaluating coagulation parameters like PT, APTT, and TT in pregnant women could offer easily acce...

The activated partial thromboplastin time-clot waveform analysis in hemophilia: Does it help in differentiation?

The clot waveform analysis (CWA) provide valuable information beyond clotting time. The present study was planned to assess whether the activated partial thromboplastin time (aPTT)-CWA can differentia... The aPTT-CWA was generated by an optical detection system (ACL-TOP™ 500 coagulation analyzer) and the other tests were performed as per instructions from the manufacturer in the kit.... A total of 75 samples (47-HA, 16-HAWI, and 12-HB) with prolonged aPTT were recruited. On analyzing the quantitative aPTT-CWA data of HA (non-inhibitors) and HB samples, the width of acceleration 1 [+]... The aPTT-CWA parameters may be supportive for the differentiation of hemophilia including its severity and the existence of inhibitors....

Risk stratification and prognostic value of prothrombin time and activated partial thromboplastin time among COVID-19 patients.

COVID-19 is a viral disease caused by a new strain of corona virus. Currently, prognosis and risk stratification of COVID-19 patients is done by the disease's clinical presentation. Therefore, identif... A follow-up study was conducted among conveniently recruited COVID-19 patients attended from March to June 2021. Socio-demographic and clinical data were collected using a structured questionnaire and... Baseline PT at a cut-off value ≥ 16.25 seconds differentiated severe COVID-19 patients from mild and moderate patients (AUC: 0.89, 95% CI: 0.83-0.95). PT also differentiated mild COVID-19 patients fro... Prolonged baseline PT was observed in severe COVID-19 patients. Prolonged baseline PT was also predicted to worsen prognosis. An increase from the baseline PT was associated with worsen prognosis. The...

A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy.

Unfractionated heparin is used to prevent coagulation activation in patients undergoing extracorporeal membrane oxygenation (ECMO) support. We designed this study to determine the preferable indicator... We conducted a retrospective study and divided the patients into an activated coagulation time (ACT)-target group and an activated partial thromboplastin time (aPTT)-target group. The correlations bet... Thirty-six patients were included (19 aPTT-target and 17 ACT-target patients); a total of 555 matched pairs of ACT/aPTT results were obtained. The correlation between the ACT and aPTT measurements was... The correlation between ACT and aPTT and the heparin dose was poor. The aPTT group had fewer daily heparin dose changes and a lower cumulative heparin dose per day than the ACT group, with no more ble...